{
    "nct_id": "NCT06313593",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms",
    "inclusion_criteria": "* Age ≥ 18 years\n* Participants with intermediate-1 or higher risk PMF, post-PV, of post-ET MF, histologically confirmed\n* Evidence of minimum burden of disease based on symptoms and/or splenomegaly\n* Life expectancy > 6 months\n* Willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease)\n* Existing documentation of JAK2V617F mutation from a qualified local laboratory\n* Previously treated with at least 1 JAK inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of a hematological malignancy requiring treatment, other than PMF, post-PV MF, or post-ET MF\n* Prior history of major bleeding or thrombosis within the 3 months prior to study enrollment\n* Participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation\n* Has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned\n* Active invasive malignancy\n* Significant concurrent, uncontrolled medical condition\n* Active HBV/HCV or known HIV\n* Any prior MF-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment\n* Participants undergoing treatment with G-CSF or GM-CSF, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
    "miscellaneous_criteria": ""
}